Status:
COMPLETED
Non-invasive Stimulation in Neurofibromatosis Type 1
Lead Sponsor:
University of Manchester
Conditions:
Neurofibromatosis 1
Eligibility:
All Genders
11-16 years
Phase:
NA
Brief Summary
Intellectual impairments are a significant cause of morbidity in children with birth defects along with long term implication on academic and occupational functioning. Long lasting functional changes ...
Detailed Description
16 children between the age of 11-16 years will be recruited through Manchester Centre of Genomic Medicine NF1 Database. The participants will be randomly assigned to 2 groups- active and sham treatme...
Eligibility Criteria
Inclusion
- children aged 11-16 years
- With a confirmed diagnosis (wither clinical or genetic) of Neurofibromatosis Type 1
- Informed consent/assent
Exclusion
- Child on active treatment for any NF1 related complications (such as chemotherapy for optic glioma)
- Children with a known history of Epilepsy or on anti-epileptic medication
- Children with poor verbal communication
- Children with cardiac pacemakers, joint replacements or metal implants will be excluded.
- Children with any previous operations to their head will be excluded.
Key Trial Info
Start Date :
October 13 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2018
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT03310996
Start Date
October 13 2017
End Date
June 30 2018
Last Update
April 24 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Manchester
Manchester, Greater Manchester, United Kingdom, M13 9QQ